Trastuzumab Rezetecan

Generic Name: Trastuzumab Rezetecan

Clinical Trials

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: SHR-A1921
Drug: SHR-A1811
Drug: Adebrelimab

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Beijing GoBroad Hospital

Target Recruit Count: 131

Registration Number: NCT06433609

Locations: 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer With HER2- Mutations

Interventions: Drug: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Drug: SHR-A1811

First Posted Date: 2024-05-28

Last Posted Date: 2025-02-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 300

Registration Number: NCT06430437

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Phase 2

Recruiting

Conditions: HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Interventions: Drug: SHR-A1811

First Posted Date: 2024-05-14

Last Posted Date: 2024-07-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT06413745

Locations: 🇨🇳
Zhongshan Hospital，Fudan University, Shanghai, Shanghai, China

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Phase 2

Not yet recruiting

Conditions: Breasr Cancer

Interventions: Drug: SHR-A1811
Drug: Bevacizumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Huihua Xiong

Target Recruit Count: 30

Registration Number: NCT06361979

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Phase 3

Recruiting

Conditions: Advanced Colorectal Cancer

Interventions: Drug: TAS-102, Regorafenib , Fruquintinib
Drug: SHR-A1811

First Posted Date: 2024-01-10

Last Posted Date: 2024-03-15

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06199973

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Phase 3

Recruiting

Conditions: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Interventions: Drug: SHR-A1811
Drug: Trastuzumab Emtansine

First Posted Date: 2023-11-13

Last Posted Date: 2025-05-02

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 1600

Registration Number: NCT06126640

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3

Recruiting

Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: SHR-A1811
Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

First Posted Date: 2023-11-08

Last Posted Date: 2024-01-16

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 360

Registration Number: NCT06123494

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Phase 2

Recruiting

Conditions: Advanced Salivary Gland Carcinoma

Interventions: Drug: SHR-A1921
Drug: SHR-A1811
Drug: SHR 3680 + leuprolide

First Posted Date: 2023-06-29

Last Posted Date: 2024-03-15

Lead Sponsor: Fudan University

Target Recruit Count: 88

Registration Number: NCT05924256

Locations: 🇨🇳
Dongmei Ji, Shanghai, China

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-A1811
Drug: TROP2 ADC

First Posted Date: 2023-04-21

Last Posted Date: 2023-06-27

Lead Sponsor: Fudan University

Target Recruit Count: 56

Registration Number: NCT05824325

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

First Posted Date: 2023-04-14

Last Posted Date: 2023-07-20

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 530

Registration Number: NCT05814354

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy